The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We ...

We compared the mutational status of the NPM1, FLT3, CEBPA, MLL, and NRAS genes in leukemia cells with the clinical outcome in 872 adults younger than 60 years of age with cytogenetically normal AML.

Primary Cutaneous B-Cell Lymphoma Treated With Radiotherapy: A Comparison of the European Organization for Research and Treatment of Cancer and the WHO Classification Systems ...

Findings from the Phase 1b portion of the study validate the clinical proof of mechanism of MTL-CEBPA as a combination treatment and identify a novel predictive biomarker of clinical response.

LONDON--(BUSINESS WIRE)--MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced final Phase 1 clinical data of MTL-CEBPA as a single agent in patients with advanced ...

A recent study has unveiled the critical roles of two transcription factors, MAFB and CEBPA, in the development of hypospadias, a common congenital malformation affecting male urethral development.

A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This ...

Drugs that slow tumor growth by targeting genetic abnormalities in the cancer itself are now well established in oncology. But what if doctors could treat cancer by altering gene activity ...

The series A round will enable MiNA to move lead drug MTL-CEBPA into a phase 2 liver cancer trial in combination with Bayer’s Nexavar. London-based MiNA has made a name for itself in recent ...